On March 15, 2019, Oncodia entered an exclusive, worldwide agreement with Temasek Life Science Laboratories, Singapore (TLL), on the commercialization of TLL’s patented PBR pattern
Easy, accurate, now!
Our vision is a world where every cancer patient receives the right therapy.
Our mission is to supply the healthcare systems with the necessary solutions to assure the best possible use of the advanced cancer drugs.
What we offer
We empower healthcare providers with CE/IVD-certified solutions from the tissue handling to the data analysis step of the diagnostic process
Approved software for analyses of tumors to guide the use of targeted therapies and checkpoint inhibitor
Fully automated extraction solution without manual reagent handling
Oncodia was awarded Eurostars grand named "3D SELECT"
The consortium of VitroScan, Anapath, FHNW, Robovision, Uppsala University and Oncodia was awarded Eurostars grant for personalized ovarian cancer therapy selection in a multidisciplinary project, named “3D SELECT”
11 July 2019
Oncodia was awarded an EIT Health Head-Start grant
10 December 2018
In a ceremony at Uppsala University Innovation, Oncodia received the "Attractive Innovation Project Award"
4-5 December 2018
Oncodia attended BioFit2018, Lille, France
What our clients say
Give us a Call 1-888-499-9240 and we can set you up, or read more about our services here
Precision medicine delivered and right therapy
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 876876
Following the Seed Round, the Board of Directors has been extended with senior expertise in medical device commercialization. Erik Hedlund, Chairman of Nolsterby Invest AB,